Four babies in Gaza crammed into one ICU cot struggle to stay alive
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Cardinal Health (NYSE:CAH) Launches One Voice Initiative Supporting Independent Pharmacy Advocacy
Cardinal Health recently launched its Cardinal Health™ One Voice Initiative, a move aimed at advocating for independent pharmacies, which aligns with the company's broader strategic efforts in product development and community support. Over the last quarter, the company's stock price rose by 22%, reflecting not only this initiative but also the increased dividend payout, which may have appealed to income-focused investors. Furthermore, Cardinal Health's inclusion in the Russell 1000 indices and a significant uptick in earnings contributed positively to investor sentiment. These developments collectively underscore the company's ability to enhance shareholder value in a relatively stable market. We've identified 1 risk for Cardinal Health that you should be aware of. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The One Voice Initiative reflects well on Cardinal Health's commitment to its independent pharmacy customers and could help bolster its brand reputation and customer satisfaction. This initiative, alongside a stronger dividend payout, aligns with its strategic emphasis on enhancing community support and product development. Over the past five years, Cardinal Health's total shareholder return, including dividends, was approximately 246.58%. This performance over the period positively positions it against the one-year broader US Healthcare industry return of 22.1% decline, demonstrating significant resilience and competitive strength. The company's strategic acquisitions and expanded manufacturing capabilities are pivotal in enhancing revenue streams. Analysts forecast annual revenue growth of 8.1%, underlined by strong performance in segments like Specialty Solutions and the onboarding of key clients like Publix. Earnings are projected to grow from US$1.6 billion to US$2 billion by May 2028. However, tariff risks and macroeconomic challenges could challenge these forecasts by impacting margins and cost structures. With a current share price of US$151.69, a discount to the consensus price target of US$175.81 suggests the market might anticipate future growth to align with analyst projections. The forecast earnings growth and other operational improvements support a fair valuation, though investors should balance these expectations with potential tariff impacts and broader economic volatility. This careful balance will likely influence Cardinal Health's trajectory in aligning with or exceeding the industry benchmarks in the coming years. Gain insights into Cardinal Health's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:CAH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Geek Wire
an hour ago
- Geek Wire
‘We will go on': Global health nonprofit PATH navigates U.S. funding freeze from new Seattle HQ
PATH's ribbon-cutting ceremony this week should have been purely celebratory. Instead, the global health nonprofit's move to airy new Seattle offices overlooking a tree-lined ship canal came as the venerable institution is finding its footing after six months of unprecedented turmoil. On the first day of his second term, President Trump froze all foreign aid. A week later, he began dismantling the U.S. Agency for International Development (USAID) — a move that could lead to 14 million additional deaths worldwide by the end of this decade, according to new research. The U.S. government has canceled awards to the organization and stalled on payments. PATH laid off roughly 45% of its global workforce, shrinking its current headcount to 1,700. 'We will go on,' Nikolaj Gilbert, president and CEO of PATH, told GeekWire. 'We will go on strong because the needs are still there, they haven't disappeared. So it's for us to challenge ourselves to see how can we continue to have even more impact with less resources.' PATH occupies a unique space in the global health sphere, doing research and testing to develop life-saving vaccines, diagnostics and medical supplies, as well as providing support for effective healthcare systems — all targeting low- and middle-income countries worldwide. It partners closely with foreign health ministries, philanthropies including the Gates Foundation, and major pharmaceutical and other companies to deliver on a mission that began nearly 50 years ago. Roger Peck, PATH's associate director of diagnostics, on a tour of the nonprofit's new lab. (GeekWire Photo / Lisa Stiffler) Navigating the aftermath The nonprofit is charting its course from the new headquarters as staff navigate the aftermath of Trump administration cuts, with the final scope of reductions still unknown. Gilbert last month shared that the nonprofit had awards for 53 U.S.-funded projects at the start of the year. By the end of May, 28 were active and 23 had been terminated; the organization did not provide an updated status. PATH expects funding from U.S. government awards to comprise 18% of its total revenue this year, down from 36% last year. The Gates Foundation remains its largest funder. Since its launch in 1977 as the Program for Appropriate Technology in Health, PATH has led and collaborated on innovations that have benefited millions of impoverished people, including: Beyond developing critical technologies, PATH works to ensure products remain affordable, reduce waste in healthcare supplies, and build local supply chains for drugs and diagnostic testing. The nonprofit is also building its artificial intelligence capabilities, hiring Bilal Mateen as its first chief AI officer nearly a year ago. PATH's AI initiatives include accelerating drug and diagnostic development and engineering an assistant to guide healthcare providers treating patients in remote areas. PATH front desk. (GeekWire Photo / Lisa Stiffler) Innovation continues despite constraints PATH operates in 70 countries through dozens of offices worldwide. More than a year ago, the organization recognized an opportunity to downsize its Seattle base as employees shifted to hybrid work following the COVID pandemic. The move from South Lake Union to Fremont cut its footprint nearly in half, from 113,000 to 52,000 square feet. But the March relocation to former Google offices wasn't just about saving space. PATH expanded its specialized lab facilities for vaccine and disease work by 20%, bringing the wet-lab area to 6,000 square feet with capacity for about 20 scientists. On a recent tour of the facility, Roger Peck, PATH's associate director of diagnostics, pointed out the wide range of scientific devices and the modular design of the infrastructure that allows for easy reconfiguration as the field evolves. 'What differentiates us is the type of work that we do here and the variety of work,' Peck said. That includes research in immunology, molecular diagnostic tests, vaccine formulations and other initiatives. The other side of the building is occupied by PATH's Product Development Engineering Lab, which feels like a makerspace and includes 3D printers, life-sized baby dolls for testing devices meant for infants and children, fabricating technologies and refrigerating systems. 'This is a really special facility because we have the capability to do complete in-house, end-to-end medical device development,' said Clara Orndorff, a global health design engineer. 'So we can do everything from prototyping to building, regulated testing to redesign, and technology transfer. In many places that would require you go to four or five different contractors.' Clara Orndorff, PATH product development engineer, explaining the mechanics of a freeze-preventive vaccine carrier, a simple but impactful device designed by PATH. (GeekWire Photo / Lisa Stiffler) Building for the future The remainder of PATH's headquarters features glass-windowed conference rooms, a spacious kitchen area that flows into an event space, offices and desks, and a casual meeting area with comfy chairs and books. Large, multimedia artwork from around the world brightens the walls and hallways. On the day of the ribbon-cutting, PATH leaders struck a tone of optimism, noting that the challenges present an opportunity for change. 'The fragility of this sector is something we could not have imagined before January of this year,' Kammerle Schneider, chief of Global Health Programs at PATH, told GeekWire. The realization has spurred PATH to accelerate long-discussed plans for creating more sustainable healthcare ecosystems and shifting the ownership of solutions to local communities. 'It's a time,' Schneider said, 'of being much more bold than perhaps we've been in the past.' Continue scrolling for additional photos. A cozy spot for informal conversations at PATH's Seattle office. (GeekWire Photo / Lisa Stiffler) PATH's entrance. (GeekWire Photo / Lisa Stiffler)
Associated Press
an hour ago
- Associated Press
The UN warns millions will die by 2029 if US funding for HIV programs isn't replaced
LONDON (AP) — Years of American-led investment into AIDS programs has reduced the number of people killed by the disease to the lowest levels seen in more than three decades and provided life-saving medicines for some of the world's most vulnerable. But in the last six months, the sudden withdrawal of U.S. money has caused a 'systemic shock,' U.N. officials warned, adding that if the funding isn't replaced, it could lead to more than 4 million AIDS-related deaths and 6 million more HIV infections by 2029. A new UNAIDS report released Thursday said the funding losses have 'already destabilized supply chains, led to the closure of health facilities, left thousands of health clinics without staff, set back prevention programs, disrupted HIV testing efforts and forced many community organizations to reduce or halt their HIV activities.' It also said that it feared other major donors scaled back their support, reversing decades of progress against AIDS worldwide — and that the strong multilateral cooperation is in jeopardy because of wars, geopolitical shifts and climate change. A 'lifeline' removed AP AUDIO: UN says if US funding for HIV programs is not replaced, millions more will die by 2029 AP correspondent Karen Chammas reports on the impact of cuts to US funding for international HIV programs. The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January, when U.S. President Donald Trump ordered that all foreign aid be suspended and later moved to shutter the U.S. AID agency. Andrew Hill, an HIV expert at the University of Liverpool who is not connected to the United Nations, said that while Trump is entitled to spend U.S. money as he sees fit, 'any responsible government would have given advance warning so countries could plan,' instead of stranding patients in Africa where clinics were closed overnight. The U.S. President's Emergency Plan for AIDS Relief, or PEPFAR, was launched in 2003 by U.S. President George W. Bush, the biggest-ever commitment by any country focused on a single disease. UNAIDS called the program a 'lifeline' for countries with high HIV rates, and said that it supported testing for 84.1 million people, treatment for 20.6 million, among other initiatives. According to data from Nigeria, PEPFAR also funded 99.9% of the country's budget for medicines taken to prevent HIV. U.N. Assistant Secretary-General Angeli Achrekar, a UNAIDS deputy executive director who was PEPFAR's principal deputy coordinator until January 2023, said the program is under review by the Trump administration though Secretary of State Marco Rubio issued a waiver 'to continue life-saving treatment.' ''The extent to which it will continue in the future, we don't know,' she told a video news conference with U.N. reporters in New York. 'We are cautiously hopeful that PEPFAR will continue to support both prevention and treatment services.' A gap impossible to fill In 2024, there were about 630,000 AIDS-related deaths worldwide, per a UNAIDS estimate — the figure has remained about the same since 2022 after peaking at about 2 million deaths in 2004. Even before the U.S. funding cuts, progress against curbing HIV was uneven. UNAIDS said that half of all new infections are in sub-Saharan Africa. Tom Ellman of Doctors Without Borders said that while some poorer countries were now moving to fund more of their own HIV programs, it would be impossible to fill the gap left by the U.S. 'There's nothing we can do that will protect these countries from the sudden, vicious withdrawal of support from the U.S.,' said Ellman, head of the group's South Africa medical unit. Experts also fear another significant loss — data. The U.S. paid for most HIV surveillance in African countries, including hospital, patient and electronic records, all of which has now abruptly ceased, according to Dr. Chris Beyrer, director of the Global Health Institute at Duke University. 'Without reliable data about how HIV is spreading, it will be incredibly hard to stop it,' he said. A new drug revives hope The uncertainty comes in the wake of a twice-yearly injectable that many hope could end HIV. Studies published last year showed that the drug from pharmaceutical maker Gilead was 100% effective in preventing the virus. At a launch event Thursday, South Africa's health minister Aaron Motsoaledi said the country would 'move mountains and rivers to make sure every adolescent girl who needs it will get it,' saying that the continent's past dependence upon US aid was 'scary.' Last month, the U.S. Food and Drug Administration approved the drug, called Yeztugo, a move that should have been a 'threshold moment' for stopping the AIDS epidemic, said Peter Maybarduk of the advocacy group Public Citizen. But activists like Maybarduk said Gilead's pricing will put it out of reach of many countries that need it. Gilead has agreed to sell generic versions of the drug in 120 poor countries with high HIV rates but has excluded nearly all of Latin America, where rates are far lower but increasing. 'We could be ending AIDS,' Maybarduk said. 'Instead, the U.S. is abandoning the fight.' ___ ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at ___
